
Rearrangements of the anaplastic lymphoma kinase (ALK) gene, which encodes for the ALK receptor tyrosine kinase, are detected in ∼5% of patients with non-small-cell lung cancer (NSCLC) with adenocarcinoma histology.1 Crizotinib was the first ALK tyrosine kinase inhibitor (TKI) approved for metastatic, ALK-positive NSCLC and was superior to platinum-based therapy in the first-line setting. However, crizotinib resistance develops due to secondary mutations...
Like
Save
Share